As we have noted above, most of the genetic alterations remove one allele of CTCF and were suggested to act as cancer drivers in breast, head and neck and uterine carcinomas (Gonzalez‐Perez et al, 2013) and endometrial cancers (Marshal et al, 2017). Here, CTCF is linked to endometrial cancer.